Primary Research on Ocular Monitoring & Management with a Targeted Oncology Product

A biopharma company wanted to inform its perspectives on potential ocular monitoring and management requirements for its targeted oncology product, which offered significant efficacy but with some risk of ocular adverse events. A clear understanding would inform decisions on clinical trial protocols, potential label discussions, and the education needed to support HCPs and patients for a positive customer experience with the product.

Our team conducted virtual interviews with a wide range of HCPs across the US, Germany, and Japan, including a mix of oncologists, ophthalmologists, and others. The discussions covered HCPs’ current process of care coordination with ophthalmologists, a brief TPP overview plus the perception of risk/benefit balance, and in-depth exploration of base case, lenient case, and strict case ocular monitoring and management protocols for the targeted product.

Using the insights gained from this research, we mapped the steps of the ocular monitoring and management journey and illuminated potential leakage, barriers, and drivers for uptake of the product. In addition, our team identified key considerations for the product’s label. Finally, we recommended tools and tactics for educating prescribers and eye care providers.

Our insights informed launch preparation for the targeted product, including cross-functional label planning and scenario planning to minimize barriers to treatment initiation and ocular monitoring.